LEGEND

enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development

Retrieved on: 
Tuesday, April 9, 2024
NMIBC, BCG, American Urological Association, Master, Professor, Advisory Council, Patient, SVP, Thesis, University, Drug, Society, American College, LEGEND, Bladder cancer, Hofstra University, FACS, Stanford University, AUA, Prostate, Medicine, Pharmaceutical industry

In this role, Dr. Pruthi's responsibilities will include supporting the clinical development of EG-70 across the urologic space, including through engagement with the urological community.

Key Points: 
  • In this role, Dr. Pruthi's responsibilities will include supporting the clinical development of EG-70 across the urologic space, including through engagement with the urological community.
  • He joins enGene from Johnson & Johnson Innovative Medicine, where he was most recently the Global Medical Affairs Leader, Bladder Cancer and Senior Medical Director, Oncology (Global – Prostate and Bladder Cancer).
  • "We are thrilled to welcome Dr. Raj Pruthi to the enGene team.
  • In addition to his position at enGene, Dr. Pruthi maintains multiple prominent leadership roles within the urological community.

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Retrieved on: 
Monday, March 18, 2024
Diagnosis, Glucose, Histology, Adipose tissue, Arm, Glycated hemoglobin, Type 2 diabetes, Disease, Connective tissue, Steatosis, Insulin, Weight gain, Diabetes, CT1, Patient, Inflammation, SGLT2, Adiponectin, Table, MASH, MD, Liver injury, Insulin resistance, LEGEND, Fibrosis, HDL, Fatty liver disease, Empagliflozin, Safety, Euronext Paris, Phase, NASH, Hepatitis, Lipid metabolism, Prediabetes, Liver disease

Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.

Key Points: 
  • Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.
  • The treatment with lanifibranor 800mg/once daily alone or in combination with empagliflozin for 24 weeks was well tolerated, with no safety concerns reported.
  • The trial is double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm.
  • More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Retrieved on: 
Thursday, February 15, 2024
LEGEND, Investigational New Drug, EIB, Data monitoring committee, European Investment Bank, SUSAR, BofA Securities, DMC, Adverse effect, Conference, Autoimmune hepatitis, Observation, Type 2 diabetes, DSM-IV codes, Patient, Fatty liver disease, Acceleration, Clinical trial, NASH, Phase, IND, NMPA, Euronext Paris, Sino Biopharmaceutical Limited, Partnership, Pharmaceutical industry

Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “2023 has been an eventful year for the company.

Key Points: 
  • Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “2023 has been an eventful year for the company.
  • This allowed us to draw down the second tranche of €25 million of the €50 million EIB loan in January 2024.
  • We have advanced our pivotal NATiV3 Phase III clinical trial with lanifibranor in NASH after the implementation of the revised study design in early 2023, with 913 patients randomized to date.
  • An adverse event of elevated aminotransferases has been reported in a patient enrolled in the trial following a scheduled visit.

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

Retrieved on: 
Tuesday, January 30, 2024
Obsidian, Assistant, Therapy, General counsel, Corporation, Bladder cancer, Bachelor of Business Administration, Health, Business administration, Law, LEGEND, University School, BCG, Sale, Urology, NMIBC, Boston Scientific, Growth, Pharmaceutical industry

Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70

Key Points: 
  • Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70
    BOSTON and MONTREAL, Jan. 30, 2024 /PRNewswire/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lee Giguere as Chief Legal Officer and Corporate Secretary.
  • "I am delighted to welcome Lee, an experienced public biotech legal executive, to enGene as we advance the development of EG-70 in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer," said Jason D. Hanson, Chief Executive Officer of enGene.
  • Mr. Giguere previously served as Chief Legal Officer and Secretary of Obsidian Therapeutics, a clinical-stage cell and gene therapy company.
  • Mr. Giguere commented: "I am thrilled to join enGene as we work to transform the management of bladder cancer, beginning with BCG-unresponsive NMIBC.

KOEI TECMO Celebrates the Global Launch of their Magical Mobile RPG Adventure, Atelier Resleriana: Forgotten Alchemy and the Polar Night Liberator!

Retrieved on: 
Thursday, January 25, 2024
Entertainment, Apps, Applications, Technology, Mobile Entertainment, Software, Internet, Electronic Games, Gems, Traditional Chinese characters, Multimedia, Android, LEGEND, Koei Tecmo, Communication, Alchemy, Atelier, KOEI, Steam, RPG, IOS

Today, KOEI TECMO Games, in cooperation with Akatsuki Games, Inc, officially launched the global version of their cinematic alchemy RPG, Atelier Resleriana: Forgotten Alchemy and the Polar Night Liberator .

Key Points: 
  • Today, KOEI TECMO Games, in cooperation with Akatsuki Games, Inc, officially launched the global version of their cinematic alchemy RPG, Atelier Resleriana: Forgotten Alchemy and the Polar Night Liberator .
  • The beautiful new addition to KOEI TECMO’s beloved Atelier universe is now available for iOS, Android and PC via Steam, complete with English, Traditional Chinese, and Simplified Chinese localized text.
  • View the full release here: https://www.businesswire.com/news/home/20240124407225/en/
    Atelier Resleriana: Forgotten Alchemy and the Polar Night Liberator features a storyline centered around two new protagonists, Resna and Valeria.
  • They live in the kingdom of Lantarna, a homeland that once thrived thanks to alchemy.

ADATA Brings Unlimited Sustainable Innovation to CES 2024

Retrieved on: 
Thursday, January 4, 2024
RGB, LCD, ATX, Ultra-wideband, TLC, SFX, Advanced driver-assistance system, AIO, LEGEND, DDR5, Electronics, LTE, DMS, Communication, CXL, ADATA, Consumer Electronics Show, XPG, EKWB, ESG, Exhibition, Light, Carbon, Safety, CES, DRAM, XTREME, Ecosystem, Edge computing, GPS, SSD, Registered, AI, HPC, Future, TCG, EDSFF, TB, Geography, Partnership, Forest Stewardship Council, Express, ADAS, LLM, Driver monitoring system, Compute Express Link, Growth, FSC, Solid-state drive, Video game

ADATA delivers the best cooling solutions for high-speed SSDs and has built the coolest SSD on the market!

Key Points: 
  • ADATA delivers the best cooling solutions for high-speed SSDs and has built the coolest SSD on the market!
  • ADATA Technology is also launching its online CES exhibition to allow global consumers to experience ADATA's innovative products without restrictions on geography or timing.
  • Lead unlimited innovation and move towards a sustainable lifestyle together with ADATA!
  • For more details, please go to the ADATA 2024 CES "Innovate for the Future" website https://event.adata.com/CES2024/en

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

Retrieved on: 
Wednesday, December 20, 2023
Phase, Marketing, GLP1, Food, MRI, Risk, NASH, Euronext Paris, FDA, Breakthrough therapy, DMC, Disease, European, Diabetes, Clinical trial, Glycated hemoglobin, LEGEND, Lipid, Fatty liver disease, NMPA, EIB, Data monitoring committee, Type 2 diabetes, SGLT2, European Investment Bank, BofA Securities, Patient, T2D, Safety, Fibrosis, Data collection, Magnetic resonance imaging, F4, Scan (company), Pharmaceutical industry

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.

Key Points: 
  • The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.
  • Analysis of the baseline characteristics of all patients randomized in the main cohort suggests a patient profile aligned with those of patients randomized in the NATIVE Phase II clinical trial.
  • Lanifibranor continues to show a favorable tolerability profile as confirmed by the third Data Monitoring Committee2 of November 2023.
  • Topline results of the proof-of-concept Phase II clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin are expected in the first quarter of 2024.

ICONIC TERRY BRADSHAW OKLAHOMA RANCH SOLD

Retrieved on: 
Tuesday, November 7, 2023
LEGEND, Sale, NFL, The Bradshaw Bunch, Horse, Bradshaw, Nature, Host, American Quarter Horse, Personality, Friends, Breeding, Marketing, Love, NCHA, DALLAS, TEXAS, Icon

DALLAS, Nov. 7, 2023 /PRNewswire/ -- The Icon Global Group has announced the completed sale of the Bradshaw Ranch owned by NFL Quarterback Legend and Host of Fox TV NFL Sunday, Terry Bradshaw.  Bradshaw recently closed the sale of his long-time ranch and home near Thackerville, Oklahoma, handing off more than twenty years of ownership.  The enormous homestead on the sprawling almost 800-acre property was also the primary filming location for E Entertainment Television's, "The Bradshaw Bunch".  The extensive property was also an intensive grazing and working cattle operation as well as being an internationally renowned breeder of world champion halter class quarter horses. It was listed on the market for $22.5 million dollars.

Key Points: 
  • DALLAS, Nov. 7, 2023 /PRNewswire/ -- The Icon Global Group has announced the completed sale of the Bradshaw Ranch owned by NFL Quarterback Legend and Host of Fox TV NFL Sunday, Terry Bradshaw.
  • Bradshaw recently closed the sale of his long-time ranch and home near Thackerville, Oklahoma, handing off more than twenty years of ownership.
  • The enormous homestead on the sprawling almost 800-acre property was also the primary filming location for E Entertainment Television's, "The Bradshaw Bunch".
  • Terry Bradshaw said, "The decision-making process to finally selling has been a long and winding road.

THE CENTER FOR DISCOVERY CEO PATRICK H. DOLLARD TO MOVE INTO SENIOR ADVISORY ROLE IN THE NEW YEAR

Retrieved on: 
Monday, October 16, 2023
MAKE, SON, LIKE, WE, RESEARCH, GOOGLE, BOARD, WORK, REALITY, SHE, ISLAND, BOLD, TCFD, THIS, LEGEND, HAS, PAY, ITS, READY, FAMILY, HERO, OR, FIRST, BUT, GREAT, WHO, COMMUNITY, DREAMS, FUTURE, GOLD, AND, Management

HARRIS, N.Y., Oct. 16, 2023 /PRNewswire/ -- THE CENTER FOR DISCOVERY® (TCFD) TODAY ANNOUNCED THAT CHIEF EXECUTIVE OFFICER PATRICK H. DOLLARD, WHO HAS LED THE ORGANIZATION FOR 43 YEARS, HAS DECIDED TO TRANSITION INTO A NEW ROLE AS SENIOR ADVISOR. THE BOARD OF DIRECTORS IMMEDIATELY NAMED DR. THERESA HAMLIN, ITS PRESIDENT, TO SUCCEED HIM. THE CHANGES ARE EFFECTIVE AT THE START OF THE NEW YEAR. 

Key Points: 
  • I HAVE REALLY ENJOYED WORKING CLOSELY WITH HIM OVER THIS PAST DECADE AND THE BOARD IS DELIGHTED HE WILL CONTINUE TO SERVE AS A SENIOR ADVISOR.
  • AS PATRICK TRANSITIONS INTO A SENIOR ADVISORY ROLE, WE ARE FORTUNATE TO HAVE DR. THERESA HAMLIN ASSUME THE CEO POSITION AT THE START OF THE NEW YEAR."
  • "TODAY TCFD IS RECOGNIZED AS A NATIONAL CENTER OF EXCELLENCE THANKS TO PATRICK'S ADVOCACY AND THOUGHT LEADERSHIP OVER FOUR DECADES.
  • "WE ARE GRATEFUL TO PATRICK FOR HIS BOLD VISION AND LEADERSHIP, AND FORTUNATE TO HAVE SOMEONE AS QUALIFIED, ENTHUSIASTIC AND READY FOR THE FUTURE AS TERRY."

enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

Retrieved on: 
Thursday, September 7, 2023
Puma Biotechnology, Bachelor, Royal college, Biotechnology, University, Therapy, RCOG, Engen Botswana Limited, Bachelor of Medicine, Bachelor of Surgery, Membership of the Royal College of Physicians of Ireland, MRCGP, RCP, Carfilzomib, DDX, Royal Navy, Onyx Pharmaceuticals, EMA, LEGEND, Science, Patient, Liposarcoma, Chief medical informatics officer, Commander of the Navy (Sri Lanka), Growth, FDA, Puma, Pharmaceutical industry, EU, NMIBC, Medicine

"We are thrilled to have Dr. Bryce join enGene during a pivotal period in our growth as we advance our Phase 1/2 registrational LEGEND study for EG-70 in NMIBC," said Jason Hanson, CEO of enGene.

Key Points: 
  • "We are thrilled to have Dr. Bryce join enGene during a pivotal period in our growth as we advance our Phase 1/2 registrational LEGEND study for EG-70 in NMIBC," said Jason Hanson, CEO of enGene.
  • Before joining enGene, Dr. Bryce was most recently Chief Medical Officer at Rain Oncology, a late-stage company developing precision oncology therapeutics, where he built a clinical development team and oversaw multiple clinical studies, including a global Phase 3 registrational study in dedifferentiated liposarcoma.
  • Prior to that, he was Chief Medical & Scientific Officer at Puma Biotechnology, where he led the development strategy for neratinib.
  • He also served as a Surgeon Lieutenant Commander in the Royal Navy.